Clinical Trials

CLINICAL TRIAL: TREMFYA

Phase lllb clinical trial, being conducted by Janssen Research and Development, evaluating Guselkumab (Tremfya) for the treatment of moderate-severe plaque or scalp psoriasis in skin of color.

 This trial consists of a 48-weeks blinded treatment period and a 100-week long term extension. During the primary 16-weeks of the trial, there will be a placebo cohort. After this, all participants will receive guselkumab 100mg Q8wks for the remainder of the treatment period and long-term extension.

 Previous trials for Tremfya included 77-93% white participants. The trial will specifically enroll patients who self-identify as a person of color. The main study requirements are listed below.

• 18 years of age or older
• Self-identify as a non-white person
• Present with active moderate-severe psoriasis for the last 6 months.
• Meet on of the following two criteria:
• BSA of 10% if presenting with body psoriasis
• BSA of 30% is only presenting with scalp psoriasis
• No previous exposure to IL-23 biologics.

 If a subject qualifies for the trial, all medical care related to the trial and the study medication, Tremfya, will be supplied as no cost. Subject will also be paid a stipend for their time and travel expenses. 

 If you have any patients that may be interested or have questions regarding the trial, please reach out to Abbey Harwell at 704-943-3714 ext. 117 or abbey.harwell@djlresearch.com.